Biological Modulation of Bacterial QSSMs, Innate and Adaptive Immunity by Antibiotics, Probiotics and Prebiotics in Healthy Individuals
Primary Purpose
Quorum Sensing, Prebiotics, Probiotics
Status
Completed
Phase
Phase 1
Locations
United Kingdom
Study Type
Interventional
Intervention
Bifidobacterium longum BB536
Active hexose correlated compound (AHCC)
Bifidobacterium longum BB536 and Active hexose correlated compound (AHCC)
Corn starch placebo capsule
Azithromycin
Sponsored by
About this trial
This is an interventional basic science trial for Quorum Sensing focused on measuring Quorum sensing, Prebiotics, Probiotics, Sepsis
Eligibility Criteria
Inclusion Criteria:
- Male volunteers
- Age 18-55 years
- Willing to participate and able to give informed consent
- Alcohol abstinence during study
Exclusion Criteria:
- Smokers/substance abusers
- Individuals with diabetes mellitus
- Oral/Intravenous steroids
- Allergy to azithromycin
- Individuals already taking regular medications/probiotics/nutritional supplements
- Individuals with chronic disease or currently under investigation
- Individuals with ≤3 bowel movements/week
- Individuals with ≥2 bowel movements/day
Sites / Locations
- University of Nottingham
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Active Comparator
Active Comparator
Active Comparator
Placebo Comparator
Arm Label
Placebo/Probiotic
Placebo/Prebiotic
Prebiotic/Probiotic
Placebo/Placebo
Arm Description
Outcomes
Primary Outcome Measures
Serum QSSM level
Secondary Outcome Measures
T cell Th1/Th2 ratio
Full Information
NCT ID
NCT01201577
First Posted
September 13, 2010
Last Updated
May 31, 2011
Sponsor
University of Nottingham
1. Study Identification
Unique Protocol Identification Number
NCT01201577
Brief Title
Biological Modulation of Bacterial QSSMs, Innate and Adaptive Immunity by Antibiotics, Probiotics and Prebiotics in Healthy Individuals
Official Title
Biological Modulation of Bacterial QSSMs, Innate and Adaptive Immunity by Antibiotics, Probiotics and Prebiotics in Healthy Individuals
Study Type
Interventional
2. Study Status
Record Verification Date
May 2011
Overall Recruitment Status
Completed
Study Start Date
October 2009 (undefined)
Primary Completion Date
May 2011 (Actual)
Study Completion Date
May 2011 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
University of Nottingham
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
It has recently been discovered that bacteria are able to communicate using specialised molecules known as Quorum Sensing Signalling Molecules (QSSMs). An accumulation of QSSMs in their surrounding environment allow for the bacteria to quantify the size of colonies. At specific colony sizes the concentration of QSSMs reaches a critical threshold leading to the activation of genes that cause an infection. It is by this mechanism that bacteria within a colony coordinate behaviour to activate infectivity when colony sizes are large enough to withstand defensive measures from the host's immune system. A disruption of quorum sensing may reduce the severity of infection and this has led to the development of inhibitors of quorum sensing as a new strategy in antibacterial therapy.
QSSMs are also thought to facilitate infection by other mechanisms and are able to influence the number and function of a specific type of immune cell known as an 'antigen presenting cell'. These cells are pivotal in allowing the immune system to recognise components of bacteria as foreign and thereby mount the appropriate response. It was found that large numbers of these types of cells underwent programmed cell death (cell suicide) in the presence of QSSMs compared to when QSSMs were absent. This mirrors the situation in blood sampled from patients with severe infections where there is a greater proportion of cell deaths among antigen presenting cells than other types of immune cell.
This study aims to establish in healthy volunteers, the mechanisms by which QSSMs affect immune cells and facilitate the spread of infection. Antibiotic administration in humans can alter the environment of the intestine and can lead to an overgrowth of harmful bacteria to potentially cause an infection. Probiotics supplements can prevent bacterial overgrowth and potentially reduce infective complications. The mechanism, which we aim to clarify, may involve changes in both the production of QSSMs and the function of immune cells.
Hypothesis
Antibiotic use alters gut flora, leading to the appearance in the systemic circulation of bacterial QSSMs and changes in immune function of the host.
Probiotics and/or prebiotics have beneficial effects by preserving the normal resident gut flora, thereby, modulating bacterial QSSMs and preserving the immune function of the host.
Aims
The aims of our study are 2 fold:
Firstly, to study the effect of orally administered antibiotic on QSSMs (in faeces and blood) and on innate and adaptive immunity in healthy humans.
Secondly, to study the effect of orally administered combinations of prebiotic, probiotic and antibiotic on QSSMs (in faeces and blood) and on innate and adaptive immunity in healthy humans.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Quorum Sensing, Prebiotics, Probiotics, Sepsis
Keywords
Quorum sensing, Prebiotics, Probiotics, Sepsis
7. Study Design
Primary Purpose
Basic Science
Study Phase
Phase 1
Interventional Study Model
Factorial Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
40 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Placebo/Probiotic
Arm Type
Active Comparator
Arm Title
Placebo/Prebiotic
Arm Type
Active Comparator
Arm Title
Prebiotic/Probiotic
Arm Type
Active Comparator
Arm Title
Placebo/Placebo
Arm Type
Placebo Comparator
Intervention Type
Dietary Supplement
Intervention Name(s)
Bifidobacterium longum BB536
Intervention Description
2 capsules od
Intervention Type
Dietary Supplement
Intervention Name(s)
Active hexose correlated compound (AHCC)
Intervention Description
One capsule tds
Intervention Type
Dietary Supplement
Intervention Name(s)
Bifidobacterium longum BB536 and Active hexose correlated compound (AHCC)
Intervention Description
One capsule tds (prebiotic) and two capsules od (probiotic)
Intervention Type
Dietary Supplement
Intervention Name(s)
Corn starch placebo capsule
Intervention Description
One capsule tds and two capsules od
Intervention Type
Drug
Intervention Name(s)
Azithromycin
Intervention Description
250mg od
Primary Outcome Measure Information:
Title
Serum QSSM level
Time Frame
14 days
Secondary Outcome Measure Information:
Title
T cell Th1/Th2 ratio
Time Frame
14 days
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Male volunteers
Age 18-55 years
Willing to participate and able to give informed consent
Alcohol abstinence during study
Exclusion Criteria:
Smokers/substance abusers
Individuals with diabetes mellitus
Oral/Intravenous steroids
Allergy to azithromycin
Individuals already taking regular medications/probiotics/nutritional supplements
Individuals with chronic disease or currently under investigation
Individuals with ≤3 bowel movements/week
Individuals with ≥2 bowel movements/day
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Abeed Chowdhury, MB ChB BSc MRCS
Organizational Affiliation
University of Nottingham
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Dileep Lobo, MBBS DM FRCS
Organizational Affiliation
University of Nottingham
Official's Role
Study Director
Facility Information:
Facility Name
University of Nottingham
City
Nottingham
State/Province
Nottinghamshire
ZIP/Postal Code
NG7 2UH
Country
United Kingdom
12. IPD Sharing Statement
Learn more about this trial
Biological Modulation of Bacterial QSSMs, Innate and Adaptive Immunity by Antibiotics, Probiotics and Prebiotics in Healthy Individuals
We'll reach out to this number within 24 hrs